It is unclear whether GLP-1 RAs and NB have comparable therapeutic effects in patients with rare genetic obesity disorders, as all these agents have been studied in patients with common obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.